scholarly journals Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis

2019 ◽  
Vol 63 (5) ◽  
Author(s):  
Amyn A. Malik ◽  
Meredith B. Brooks ◽  
Sara Siddiqui ◽  
Junaid Fuad ◽  
Charles A. Peloquin ◽  
...  
Keyword(s):  
Drug Exposure ◽  
Preventive Therapy ◽  
World Health ◽  
Serum Drug Concentration ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Drug Concentrations ◽  
Exposure Target ◽  
Health Organization

ABSTRACT Levofloxacin is used to treat and prevent drug-resistant tuberculosis in children. We assessed levofloxacin serum drug concentrations in 24 children aged 2 to 10 years who received levofloxacin-based tuberculosis preventive therapy in Karachi, Pakistan. Only 9 children (37.5%) achieved adequate drug exposure. Target serum drug concentration was met in 4 (26.7%) of 15 children dosed consistently with World Health Organization recommendations and 4 (80.0%) of 5 who received higher-than-recommended doses. Levofloxacin dosing recommendations may require reevaluation.

scholarly journals Directrices unificadas de la OMS sobre el tratamiento de la tuberculosis farmacorresistente

2020 ◽  
Keyword(s):  
World Health Organization ◽  
Tuberculosis Treatment ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Health Organization

Estas directrices unificadas se han actualizado con arreglo a los procesos del grupo de elaboración de las directrices que se llevaron a cabo entre el 2011 y el 2018 de conformidad con los requisitos de la OMS. Este documento sustituye a otras recomendaciones de la OMS relativas al tratamiento de la tuberculosis (TB) multirresistente y resistente a la rifampicina (TB-MDR/RR) publicadas desde el 201. En este documento se incluyen las preguntas sobre población, intervención, comparador y resultado (PICO, por su sigla en inglés) subyacentes a las recomendaciones y la posología revisada de los medicamentos utilizados en los esquemas de segunda línea, así como las referencias clave. En línea se puede encontrar más información sobre los procesos del grupo de elaboración de las directrices y los participantes en dicho grupo, los principales métodos utilizados para desarrollar las recomendaciones, los resúmenes de la evidencia de la clasificación de la valoración, elaboración y evaluación de las recomendaciones (GRADE por su sigla en inglés) resultante y los marcos de decisión para cada recomendación, así como datos inéditos, planes de análisis de datos e informes de revisiones sistemáticas. Las recomendaciones y demás información práctica para apoyar su implementación se reproducirán en una próxima actualización del manual de la OMS sobre el manejo programático de la TB. Versión oficial en español de la obra original en inglés: WHO consolidated guidelines on drug-resistant tuberculosis treatment. © World Health Organization 2019. ISBN: 978-92-4-155052-9.

scholarly journals The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines

2019 ◽  
Vol 54 (4) ◽  
pp. 1901272 ◽  
Author(s):  
José A. Caminero ◽  
Alberto L. García-Basteiro ◽  
Adrián Rendon ◽  
Alberto Piubello ◽  
Emanuele Pontali ◽  
...  
Keyword(s):  
World Health Organization ◽  
Tuberculosis Treatment ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
The Past ◽  
Resistant Tuberculosis ◽  
The Future ◽  
Health Organization

scholarly journals Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019

2020 ◽  
Vol 98 (1) ◽  
pp. 5-15
Author(s):  
D. A. Ivanova ◽  
S. E. Borisov ◽  
O. V. Rodina ◽  
A. V. Filippov ◽  
T. N. Ivanushkina ◽  
...  
Keyword(s):  
Risk Factors ◽  
World Health ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Treatment Regimens ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Group A ◽  
Health Organization

The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.

scholarly journals World Health Organization reports highest rates of drug-resistant tuberculosis to date

2008 ◽  
Vol 13 (12) ◽  
pp. 11-12 ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
Drug Resistance ◽  
World Health Organization ◽  
Multidrug Resistant ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Fourth Report ◽  
The World ◽  
Health Organization

On 26 February 2008, the World Health Organization (WHO) published its fourth report on the global situation regarding drug resistance in tuberculosis (TB). The report, based on information collected between 2002 and 2006 on 90,000 TB patients in 81 countries, found that 5.3% of the nine million new cases of TB each year are multidrug-resistant (MDR). This is the highest rate yet recorded.

scholarly journals World TB Day 2018: The Challenge of Drug Resistant Tuberculosis

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 217 ◽  
Author(s):  
Ankur Gupta-Wright ◽  
Gillian S Tomlinson ◽  
Molebogeng X Rangaka ◽  
Helen A Fletcher
Keyword(s):  
Mycobacterium Tuberculosis ◽  
World Health Organization ◽  
Scientific Community ◽  
World Health ◽  
Drug Resistant ◽  
Free World ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
The World ◽  
Health Organization

On 24th March, the world commemorates the day in 1882 when Dr Robert Koch announced his discovery of Mycobacterium tuberculosis (MTB). Over 130 years later, tuberculosis (TB) continues to affect individuals, communities, and entire health systems and economies. Koch unsuccessfully tried to ‘cure’ TB, and despite major advances in other areas of medicine, control of TB remains elusive- in 2016 TB was the leading infectious cause of death. The STOP TB partnership and World Health Organization (WHO) have announced their theme for World TB Day 2018 “Wanted: Leaders for a TB-Free World. You can make history. End TB.” This theme recognizes that TB is much larger than any one person, institute or discipline of research, and provides an opportunity for us to reflect on the major challenges and consider how we, as a scientific community, can work together and take the lead to address the global crisis of drug-resistant TB (DR-TB).

Drug-resistant tuberculosis: World Health Organization launches Global Response Plan 2007-2008

2007 ◽  
Vol 12 (27) ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
Global Response ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Resistant Strains ◽  
Response Plan ◽  
Health Organization ◽  
Drug Resistant Strains

An increasing proportion of tuberculosis (TB) cases today are resistant to first line, and often also to second line anti-TB drugs. Drug-resistant strains of Mycobacterium tuberculosis are now responsible for over 400,000 cases of TB per year.

Sign in / Sign up

Export Citation Format

Share Document